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Objectives: In the management of HIV infection, tenofovir is preferred to its predecessors – zidovudine and
stavudine – in the antiretroviral therapy (ART) nucleoside backbone. Tenofovir’s (TDF) preference is based on its
safety profile. Nevertheless, TDF causes adverse reactions, some of which warrant its substitution for patients.
The rate of TDF-substitution is suggestive of the rate of occurrence of TDF-related adverse reactions. However,
the rate of substitution of TDF with another nucleoside reverse transcriptase inhibitor (NRTI) in Namibia was unknown.
The objective of this review was to measure the rate of TDF’s substitution for the period of January 1, 2008 to
November 30, 2011, and to compare the gender difference in the rates of TDF’s substitution.
Methods: We accessed antiretroviral medicine dispensing records from the national antiretroviral dispensing
database (NDB). We selected patients who were started on a TDF-containing conventional ART regimen – 2NRTI+1NNRT.
We used the initial and current ART regimens to identify records of TDF’s substitution with another NRTI.
Results: A total of 84,741 patients were initiated on ART (Jan-1-2008 to Nov-30-2011). A total of 52,612 patient-records
were excluded from the analysis because they did not meet the criteria for inclusion. Of the 32,129 included records,
59.4% (n=19 096) and 40.6% (n=13 033) were for female and male patients, respectively. Of these, 1.2% (n=380) of the
patients had their TDF substituted with another NRTI. Of the females and males, respectively, 1.1% (95% CI: 0.9-1.3;
n=210) and 1.3% (95% CI: 1.1-1.5; n=170) had TDF substituted with another NRTI. No gender difference was observed
(p-value = 0.11).
Conclusion: The percentage of patients for whom TDF was substituted with another NRTI, possibly due to TDF-related
adverse reactions, was within the current published limits. However, 1.2% is likely not a true representation of the
percentage of patients who experience adverse events because some patients could have been maintained on
TDF even in the presence of adverse events. Further investigation is required to determine the clinical reasons for
TDF’s withdrawal.
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Tenofovir (TDF) is an acyclic nucleotide analogue that is
used for the treatment of the human immunodeficiency
virus (HIV) infection. TDF in combination with lamivu-
dine (3TC) is effective against Hepatitis-B virus, making
the TDF/3TC nucleoside backbone a better choice for
Hepatitis-B/HIV co-infected patients [1]. TDF is a nucleo-
tide reverse transcriptase inhibitor, but it is also classified* Correspondence: fkalemeera@unam.na
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In this paper TDF is referred to as an NRTI.
Currently, the combination of TDF and 3TC or emtrici-
tabine (FTC) is the preferred nucleoside backbone of the
first line antiretroviral therapy (ART) [3,4]. Previously,
stavudine-(d4T) combined with 3TC was the preferred
NRTI backbone of first-line ART. However, due to an in-
creased incidence of d4T-associated toxicities, including:
peripheral neuropathy, lipoatrophy, lactic acidosis, and
pancreatitis [5-7], d4T was replaced by zidovudine (AZT).
Similarly, AZT’s place was taken by TDF due to a rela-
tively high incidence of AZT-associated anaemia, and less
frequently lipoatrophy. Because the TDF-based first linetral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Kalemeera et al. Journal of Pharmaceutical Policy and Practice  (2015) 8:14 Page 2 of 5ART regimen was as effective as the d4T- and AZT-based
regimens, and also because the cost of acquisition of TDF
was low [8], TDF’s position in the NRTI backbone of the
first-line ART regimen was secured by TDF’s better safety
profile. Nevertheless, TDF is known to cause adverse reac-
tions in the gastrointestinal tract, renal system, and skel-
eton system. In the skeletal system, TDF has been shown
to be associated with bone demineralisation, which is mea-
sured through the use of Dual Energy X-ray Absorpti-
ometry (DEXA). Some adverse reactions may be more
common in females than in males, as is the case for liver
related reactions [9,10].
In the kidneys, TDF destabilises the re-absorptive cap-
acity and secretory function of the proximal tubules result-
ing in the loss of filtered compounds such as glucose,
proteins and phosphate in the urine, coupled with the re-
duced secretion of protons and TDF [11]. Recent evidence
suggests that TDF-associated proximal tubulopathy is due
to mitochondrial toxicity. This evidence is founded on bi-
opsy results that have shown mitochondrial damage in the
proximal tubular cells in patients with renal insufficiency
while taking TDF-containing ART. It is believed that inhib-
ition of mitochondrial DNA-polymerase gamma, an NRTI-
class related mechanism of mitochondrial dysfunction,
underlies TDF-associated proximal tubulophathy [1,11,12].
In 2010, TDF + 3TC became the preferred NRTI back-
bone for first line ART in Namibia. Previously, TDF had
been preserved for second line ART. Eventually, a large
number of patients were started on TDF-based ART. Like
its predecessor antiretroviral medicines, TDF is associated
with serious adverse reactions that call for its withdrawal
should they occur. In this regard, the frequency of substitu-
tion of TDF with another NRTI is suggestive of a TDF-
associated adverse reaction. Another possible reason for
substitution of TDF with another NRTI would possibly be
treatment failure. However, the rate of TDF’s withdrawal
and substitution, in Namibia, was unknown. Consequently,
we reviewed the National ART dispensing database of
Namibia to provide insight into the percentage of patients
who may not tolerate TDF.
Objectives
The primary objective of this review was to assess the
rates of substitution of TDF with another NRTI as first
line ART, and the secondary objective was to compare




In this retrospective cohort study, we assessed antiretro-
viral dispensing records of patients who were started on
ART from January 1, 2008 to November 30, 2011. The
National Antiretroviral Database (NDB) was the sole sourceof records. The primary outcome was the substitution of
TDF with another antiretroviral medicine, while the Co-
administered medicines remained unchanged.
Inclusion and exclusion criteria
All public health facilities that provided ART in Namibia
from January 2008 to November 31, 2011 were included.
The ART dispensing records of interest were for patients
who were initiated on the conventional first line regimen,
i.e., 2NRTI + 1NNRTI, in the period stated. The two regi-
mens were TDF/3TC combined with EFV or NVP. Records
for adult patients, as defined by the World Health Organ-
isation (WHO), were included. Records that indicated the
withdrawal of TDF and the NNRTI were excluded, because
that type of substitution indicated the occurrence of treat-
ment failure. Also, we excluded records of patients who
were on TDF-sparing regimens at the start of ART; and re-
cords of those with non-conventional starting regimens
even though they were TDF-containing, because some of
them were second-line regimens and clinical justification
for their use was not available.
Study procedures
We retrieved the automated records of the dispensing of
antiretroviral medicines from the national database in an
Excel format for the period of January 1, 2008 to November
30, 2011. In regards to antiretroviral medicines dispensed,
the national database provided the starting and current
ART regimens. The records which were included in the
analysis were for patients who were started on TDF/3TC/
NVP or EFV. We identified records of those for whom
TDF was replaced by another NRTI.
Ethical approval
Patient consent was not sought because patient informa-
tion was sourced from existing databases and clinical re-
cords without requiring additional information directly
from patients. ART dispensing data were captured in the
national database housed in the Ministry of Health and
Social Services’ Division of Pharmaceutical Services.
Only TIPC staff members mandated by the Ministry of
Health and Social Services to implement medicines
safety analyses were involved in the medical record ab-
straction process and in the epidemiological study con-
sidered to be a public health activity. Precautionary
measures were followed to maximize the confidentiality
by removing all personal identifying information.
Analysis
We used descriptive methods, and the Students-T test
for the comparison between female and male patients’
TDF-substitution rates. We set the confidence level at
95% and the statistical significance at a p-value of <0.05.
Figure 1 Percentage of patients changed from TDF to another NRTI.
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A total of 84,741 patients were started on ART from
January 1, 2008 to November 30, 2011. Of these 50,252 pa-
tients was started on TDF-sparing regimens, and so were
excluded from the analysis. Furthermore, we excluded 326
patients younger than 18 years of age at the start of ART,
leaving 34,163 records. Amongst these, 2,034 patients were
started on either a non-conventional first line ART regimen
or on second line therapy, and so they were excluded from
the analysis, leaving a total of 32,129 patient records for
analysis. Of these 32,129 patients 59.4% (n = 19,096) were
female and 40.6% (n = 13,033) were male.
Distribution according to year of ART initiation
Of the 32,129 patients who were started on TDF/3TC/
EFV or TDF/3TC/NVP the number of persons by year is
as follows: 2,865 in 2008; 3,497 in 2009; 8,666 in 2010;
and 17,101 in 2011 (Table 1).
Number and percentage of patients for whom TDF was
substituted
Of the 32,129 patients, 1.2% (n = 380) patients had TDF
substituted with another NRTI leaving 31,749 on TDF-
based ART (Table 1). Of those for whom TDF was
substituted, 210 and 170 were female and male, respectively
(Table 1). The percentage (and number) of substitutions of
TDF with another NRTI that were implemented per year,
from 2008 to 2011, was as follows: 0.80% (n = 23) in 2008;
1.43% (n = 50) in 2009; 1.63% (n = 141) in 2010; and 0.97%
(n = 166) in 2011. (Figure 1, Table 1). The overall percent-
age of female patients that were changed from TDF to an-
other NRTI was 1.1% [CI 0.9-1.3] and for the males it was
1.3% [CI 1.1-1.5], (p-value = 0.11).
Discussion
In settings with relatively efficient availability and acces-
sibility of antiretroviral medicines, such as Namibia [4],
the most likely reason for substitution of TDF with an-
other NRTI is occurrence of severe adverse reactions.
While the reasons for substitution were not assessed in
this study, it is likely that the replacement of TDF with
another NRTI without alteration to the other antiretro-
viral medicines in the regimen was prompted by TDF-Table 1 Comparison between female and male percentages o
Period
(Years)




Total (N) Female: n (%) Male: n (%) Female
2008 2,898 1,642 (56.7) 1,256 (43.3) 18 (1.1: 0.6 – 1.6)
2009 3,536 1,889 (53.4) 1,647 (46.6) 32 (1.7: 1.1 – 2.3)
2010 8,666 5,100 (58.9) 3,566 (41.1) 71 (1.4: 0.9 – 1.9)
2011 17,101 10,465 (61.2) 6,636 (38.8) 89 (0.8: 0.5 – 1.1)
TOTAL 32,129 19,096 (59.4) 13,033 (40.6) 210 (1.1: 0.9 – 1.3)associated adverse reactions. The percentage of patients,
for whom TDF was substituted with another NRTI from
2008 to 2011 was low (1.2%: 380 out of 32 129). This
value is somewhat lower than in published literature:
5.5% for all causes [13]; 3% for renal events [14]; and
28% for bone demineralisation [9]. According to the
spontaneously reported adverse event data in Namibia’s
national pharmacovigilance centre, TDF was reported to be
associated with intractable diarrhoea, intractable vomiting,
and renal impairment, but not osteopenia, osteoporosis, or
fractures (unpublished observations).
Since the Namibia ART guidelines that were in effect
from 2008 to 2011 recommended the substitution of TDF
with another NRTI in the event of occurrence of a severe
adverse reaction [15,16], it is plausible that substitution of
TDF with another NRTI was prompted by adverse reac-
tions. According to TDF’s prescribing information, diar-
rhoea, nausea, vomiting and dyspepsia are listed amongst
TDF-associated gastrointestinal (GI) side effects [1]. The
presentation of GI side effects is usually clear, and they can
guide the decision to continue or stop administration of
TDF. For example: mild to moderate gastrointestinal effects
may not, but more serious ones such as intractable vomit-
ing and intractable diarrhoea, may necessitate TDF’s substi-
tution with another NRTI. In all cases, the decision to
withdraw TDF should be dependent on the appropriate as-
sessment of causality of the event, including the ruling-outf patients changed from TDF to another NRTI
en females and males: Number (Percentage: confidence interval of
rom TDF
Male p-value
5 (0.4: -0.1 – 0.9) 0.03
18 (1.1: 0.5 – 1.7) 0.13
70 (1.9: 1.7 – 2.6) 0.01
77 (1.2: 0.9 – 1.5) 0.01
170 (1.3: 1.1 – 1.5) 0.11
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were amongst the reasons for TDF’s withdrawal, which is
evidenced by reports in TIPC’s database of adverse reac-
tions (unpublished observation).
In some instances, TDF-associated renal insufficiency
is slow and conspicuous in development such that its
early detection necessitates frequent renal function tests
(RFT) [17,18]. Since the Namibia’s ART guidelines recom-
mended regular RFTs – particularly, the calculation of the
GFR – for patients on TDF-containing ART, we believe
that the detection of renal impairment was one of the
major reasons for TDF’s substitution [18]. The manifest-
ation of reduced GFR was not considered a pre-requisite
for substitution of TDF according to Namibia’s ART guide-
lines. In such instances, TDF’s dosing interval would be
lengthened, thus fostering the pathological process of renal
tubular damage, if indeed TDF was the primary cause of
renal insufficiency [18]. On this basis, there is reason to be-
lieve that the substitution of TDF, due to abnormal RFT
was prompted by a very low GFR <30mls/minute. At times,
patients taking TDF-based ART experience acute renal fail-
ure and the Fanconi Syndrome [1,19], and TDF’s prompt
and permanent withdrawal would be implemented [13].
Evidence of TDF-associated renal insufficiency as a cause
for TDF’s withdrawal is available in TIPC’s database of ad-
verse reactions (unpublished observation). In regards to
gender, our results suggest that gender did not have any in-
fluence on the rate of substitution from TDF to another
NRTI (p-value = 0.11).
TDF is known to reduce bone mineral density resulting
in osteopenia and osteoporosis, which could be secondary
to TDF-associated renal impairment [1,20]. The pain asso-
ciated with bone fragility and the resultant fractures are a
strong basis for TDF-substitution. While a decrease of
bone mineral density as a TDF-related adverse effect is
mentioned in Namibia’s ART guidelines, the use of DEXA
to measure bone demineralisation in patients taking TDF
is not recommended in Namibia’s ART guidelines. This is
possibly due to the fact that DEXA is only available in pri-
vate practice settings in Namibia. Therefore, it is not pos-
sible to assume that osteopenia, osteoporosis, and the
resultant fractures contributed to the substitution of TDF.
It is unlikely that treatment failure was a reason for
TDF’s withdrawal and replacement with another NRTI.
This is because Namibia’s ART guidelines that were in
force at the time of this review recommended that TDF
and 3TC should be maintained in second line therapy,
while EFV or NVP are replaced with LPV-r and AZT [18].
Moreover, for the 380 patients whose TDF was substituted
with another NRTI, EFV- or NVP were retained on the
ART regimen thus ruling out the plausibility that treat-
ment failure had occurred.
Our findings were limited by a number of issues. First:
we eliminated from the analysis patients who were changedfrom a TDF-containing ART regimen to a non-conventional
TDF-sparing ART first line regimen, yet amongst these
some may have experienced a TDF-related adverse re-
action. Secondly: because renal insufficiency is not a pre-
requisite to substitute TDF until the GFR is <30mls/min,
it is possible that a number of patients, who were still on
TDF at the time of this review, may have developed renal
insufficiency, but still at a low grade such that TDF was
maintained. Moreover, the NDB lacked data on the ad-
justed dose of TDF so that patients with reduced GFR
could not be identified. Lastly: our analysis was based on
data from the NDB, which lacked information on the ad-
verse reactions that the patient may have experienced.
Therefore, it was not possible to allocate percentages of
patients to GI-, renal-, and bone- related adverse events.
Conclusion
The percentage of patients for whom TDF was replaced
with another NRTI, possibly due to adverse reactions, was
within the current published values. There was no signifi-
cant difference between TDF substitution between females
and males. Since the ART guidelines recommended that
following the detection of renal insufficiency of lower se-
verity grades, TDF’s dose was to be recalculated and its ad-
ministration maintained, it is possible that some patients
with renal insufficiency remained on TDF. Furthermore,
the paucity of tests to assess bone mineral density means
that patients who may have had osteopenia and osteopor-
osis associated with TDF could have remained on TDF-
based therapy. Therefore, the estimated percentage (1.2%)
of patients whose TDF was replaced with another NRTI is
unlikely to be a true representation of the percentage of
patients that do not tolerate TDF in Namibia. Further ana-
lysis is required to determine the actual events that led to
TDF’s withdrawal, and to review patient treatment notes
for complaints of bone pain and events of fractures. Also,
there is need to review data for patients who were initiated
on TDF-based first line therapy when they were younger
than 18 years of age. Further studies are needed to esti-
mate the prevalence of different types of TDF associated
adverse reactions; and to detect the average time of mani-
festation of these adverse events after initiation of ART.
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